



TECHNOLOGY EVALUATION CONSORTIUM™

Quantitative Medicine Meeting with Pfizer and Amgen
ToxCast Study Results
Friday, September 13, 2013
Webinar

Cambridge Healthtech Associates

Dawn Van Dam (General Manager)
Amid Zand (Project Manager)
Ernie Bush (Scientific Director)

Quantitative Medicine

John King
Geoff Hoare
Joshua Kangas
David Demosthenes
Jim Parrino (not on call)
Bob Murphy (not on call)
Jamie Grooms (not on call)
Scott Bodine (not on call)

Amgen

Padma Narayanan
Chuck Qualls (not on call)
Helen McBride (not on call)
Yudong He (not on call)

Pfizer

Yvonne Will
Falgun Shah

Agenda

- I) Data Presentation: ToxCast Assessment (Quantitative Medicine)
 - II) Closing and Action Items
-

I) Data Presentation: ToxCast Study Assessment

Joshua Kangas gave the Quantitative Medicine presentation, covering several major topics as outlined by the Quantitative Medicine slides:

ToxCast Study Design

The ToxCast study conducted was outlined in a general sense. The data used for the study was summarized, intended predictions were outlined and prediction accuracy assessment was explained.

Simulation Results

The results of the simulation study were represented graphically and described in detail.

Prospective Uses

Real world potential uses specifically relevant to the participating parties were discussed.

Next Study

The Amgen team expressed its inability to say whether or not they could consider an additional study at this time.

Josh suggested future studies using additional ToxCast data or data from the participating companies and requested feedback from the Pfizer and Amgen teams.

John explained that the nature of Quantitative Medicine's system is such that its power evolves through the establishment and maintenance of a relationship between Quantitative Medicine and a company such as those involved in this study.

Yvonne of the Pfizer team explained that she may still be lacking some understanding of the system and that there is obviously a need for her team to have an internal discussion. The Pfizer team explained that experts in the relevant departments would need compelling proof of concept to consider implementation of a system like that of Quantitative Medicine.

Josh suggested an additional study to the Pfizer and Amgen teams which could act as further proof of concept.

The Pfizer team expressed interest in Josh's suggestion of an additional proof of concept study.

II) Closing Remarks and Action Items

The Pfizer team expressed their intention to have an internal discussion about what data they may possess to possibly pursue an additional proof of concept study. They would then communicate their thoughts to the group.

The Amgen team also expressed interest in a possible additional proof of concept study. They also planned to have an internal discussion then communicate with Quantitative Medicine and CHA. Padma strongly suggested that Quantitative Medicine have a conversation with Yudong He, who had also done work on the ToxCast data.

Dawn expressed interest in facilitating said discussion between Yudong and Quantitative Medicine.

Josh expressed his desire that as the Pfizer and Amgen teams are discussing further study designs, they consider the notion that the claim being made is that Quantitative Medicine can build a model more efficiently with less experimentation. Therefore, the greatest benefit of the system can be observed while the experimentation is actually taking place.

The Pfizer team suggested possibly providing Quantitative Medicine with a few compounds for them to classify using their system, as an additional method of validation.

CHA planned to continue facilitation of communication between all parties.